PARSIPPANY, N.J., July 26 /PRNewswire/ -- Daiichi Sankyo, Inc. announced today that the U.S. Food and Drug Administration (FDA) approved TRIBENZOR™ (olmesartan medoxomil, amlodipine, hydrochlorothiazide), a new three-in-one combination product taken once-daily for the treatment of hypertension in patients who are not adequately controlled on any two of the following antihypertensive drug classes: angiotensin receptor blockers, calcium channel blockers and diuretics. TRIBENZOR is not indicated for initial therapy.(
